Skip to main content
SMMT logo

SMMT · Summit Therapeutics Inc.

Track SMMT — free
$11.82 -2.33 (-16.47%) At close · Nov 16
Market Cap
$9.45B
Shares
799.76M
Volume · Nov 16 24.45M Avg daily vol (3M) 6.46M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$11.82 Open$12.71 Day$11.53–13.28 52W close$11.82–26.38 Avg vol 30d5.8M Short int42.3M · 5.3% of shares · 9.4d Short vol43% Last earningsNov 4, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 4

Up next

Feb 22, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 16
Current report 8-K Events of Nov 15
FDA Issues CRL for Ivonescimab Lung Cancer Application

Summit Therapeutics said the FDA issued a Complete Response Letter (CRL) for ivonescimab in non-small cell lung cancer, saying the application cannot be approved in its present form without a statistically significant overall survival improvement.

Other events
2 source passages
Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for ivonescimab in combination with platinum-containing chemotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), who have received prior epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy. The CRL indicates that the BLA cannot be approved in its present form, as the FDA determined that substantial evidence of effectiveness is not established in the absence of a statistically significant overall survival (OS) improvement. Open the document at this passage
Nov 4
Current report 8-K
108,955,369 common shares cleared for resale and issuance

Summit Therapeutics Inc.’s prospectus supplement covers resale of up to 108,955,369 common shares issuable on preferred-stock conversion; Baker & Hostetler LLP opined they will be validly issued, fully paid and nonassessable.

Other events
2 source passages
The Prospectus Supplement relates to the offer and resale from time to time by the selling stockholder identified in the Prospectus Supplement (the “Selling Stockholder”) of up to 108,955,369 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (the “Common Stock”), issuable upon the conversion of 108,955.3686 shares of Class A Convertible Preferred Stock, par value $0.01 per share (the “Preferred Shares”), held by the Selling Stockholder. Based on the foregoing, and subject to the qualifications stated herein, we are of the opinion that when the Shares shall have been duly registered on the books of the transfer agent and registrar therefor in the name of or on behalf of the Selling Stockholder, and have been issued by the Company in the circumstances contemplated by the Preferred Shares, the Shares will have been duly authorized by all necessary corporate action of the Company and the Shares will be validly issued, fully paid and nonassessable. Open the document at this passage
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Ivonescimab FDA action date set for November 14, 2026

Summit Therapeutics’ ivonescimab BLA was accepted in January 2026, with an FDA action date of November 14, 2026. A June 2026 analysis showed an OS hazard ratio of 0.76 (nominal p=0.0151), but FDA requires a statistically significant OS benefit.

Net loss $208.39M Diluted EPS -$0.26
Read from the MD&A section
4 source passages
Summit Therapeutics Inc. (“we,” “Summit” or the “Company”) is a biopharmaceutical company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Summit announced in January 2026 that the FDA accepted for filing the BLA seeking approval for ivonescimab in combination with chemotherapy for this proposed indication. The FDA provided a Prescription Drug User Fee Act (“PDUFA”) goal action date of November 14, 2026. The updated June 2026 analysis, which was presented as part of the Presidential Symposium at the International Association for the Study of Lung Cancer (“IASLC”) 2026 World Conference on Lung Cancer (“WCLC”), continued to show consistent, favorable OS results, with an OS hazard ratio of 0.76 (95% CI: 0.61 – 0.95; nominal p=0.0151) in the global intention-to-treat (“ITT”) population. The FDA noted that a statistically significant OS benefit is necessary to support marketing authorization in this setting, and the PFS results from this study may not be sufficient to support marketing authorization. Open the document at this passage
Nov 4
Current report 8-K
Ivonescimab FDA PDUFA goal date set for November 14, 2026

Summit Therapeutics reported third-quarter results ended September 30, 2026, with $629.8 million cash and investments, a $2.0 billion AstraZeneca investment, an FDA PDUFA goal action date of November 14, 2026 for ivonescimab, and a HARMONi overall-survival hazard ratio of 0.76.

Financial results, Charter or bylaw amendment, or fiscal year change, Shareholder vote results
5 source passages
Summit Therapeutics Inc. (NASDAQ: SMMT) today reported its financial results for the third quarter and nine months ended September 30, 2026, and provided an update on clinical and operational progress. Aggregate cash and cash equivalents and short-term investments were $629.8 million and $713.4 million at September 30, 2026 and December 31, 2025, respectively. On October 5, 2026, AstraZeneca completed a $2.0 billion strategic equity investment in Summit. The FDA provided a Prescription Drug User Fee Act (PDUFA) goal action date of November 14, 2026. The updated June 2026 analysis continued to show consistent, favorable OS results, with an OS hazard ratio of 0.76 (95% CI: 0.61 – 0.95; nominal p=0.0151) in the global intention-to-treat (ITT) population. Open the document at this passage
Oct 19
Proxy statement DEF 14A Meeting Nov 4, 2026
Proxy statement

Summit Therapeutics is holding a virtual special meeting on November 4, 2026 at 11:00 a.m. Eastern Time to seek stockholder approval of an amendment increasing authorized common stock from 1,000,000,000 to 2,000,000,000 shares.

Read from the first part of this long document
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$832.68M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-4.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$629.79M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+7.4%
Year over year · more shares
Price change (1Y)
-22.5%
Trailing year
Short interest
5.3%
Latest settlement · 9.4 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −27%
below
Price vs 50-day avg −27%
below
RSI (14) 35
neutral
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −24%
trailing
6-month return −32%
trailing
YTD return −32%
this year
Relative strength −31%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $16 › 200d $16 — 50d above 200d
Institutional flow Accumulating
+3% holders QoQ · +74 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
5.28% of shares out · ▲ +3.3% MoM · 9.4 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
257 holders — near 3-yr high, broad support
Squeeze score 65
elevated · 0–100
Fundamentals
Weak
EPS growth −365%
Y/Y
Free cash flow $-323.6M
Balance sheet $225.3M
net cash
Quant / Vol
risk profile
Very High
Volatility 78%
annualized · 1-yr
Max drawdown −55%
past year
ATR 11.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−27% Bearish
Price vs 50-day avg
−27% Bearish
RSI (14)
35 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $16 › 200d $16 — 50d above 200d
Institutional flow Accumulating
+3% holders QoQ · +74 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
5.28% of shares out · ▲ +3.3% MoM · 9.4 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
257 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $12 Now $12 · 0% Range high $26
vs 200-day avg -27% vs 50-day avg -27%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SMMT
Summit Therapeutics Inc.
this stock
$9.45B -32.4% — — 5.3%
VRTX
Vertex Pharmaceuticals Inc
$136.35B +18.6% +46.2% 34.6 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$98.52B +23.4% +20.8% 21.1 2.1%
MRNA
Moderna, Inc.
$87.10B +630.0% +4.3% — 8.2%
CSLLY
Csl Ltd
$65.26B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
257
% held
11.0%
Net QoQ
-48.1M sh
Top holder
BAKER BROS. ADVISORS LP
Held Float
View
Held by Funds
Fund positions
188
View
Short & Settlement
Short Interest Rising
Shares short
42.3M
Days to cover
9.4d
Change
+1.4M sh
View
Short Volume
Short vol %
43%
As of
Nov 16, 2026
Short Total
View
Fails to Deliver
FTD shares
557
Value
$8.7K
As of
Oct 23, 2026
View
Off-Exchange
Off-exchange %
46.0%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-1.1B
EPS diluted
$-1.44
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 16, 2026
This year
32

Summit Therapeutics said the FDA issued a Complete Response Letter (CRL) for ivonescimab in non-small cell lung cancer, saying the application cannot be approved in its present form without a statistically significant overall survival improvement.

View
Exempt Offerings
Offering
$235.0M
Filed
Sep 26, 2024
View
Earnings & Events
Webcasts
Last webcast
Nov 4, 2026
View
Investor Relations
Latest news
Summit Therapeutics Provides Upda…
Published
Nov 15, 2026
View

Performance

5D 20D 120D MTD YTD
SMMT -33.7% -24.1% -31.9% -26.3% -32.4%
SPY -1.7% -3.5% -1.4% -2.1% +8.5%
vs SPY -32.1% -20.6% -30.5% -24.2% -40.9%
Key facts CIK 1599298 CUSIP 86627T108 13F (30d) 265 filings 248 filers Visit website Investor relations